CRK proteins selectively regulate T cell migration into inflamed tissues

Yanping Huang,1 Fiona Clarke,1 Mobin Karimi,2 Nathan H. Roy,1 Edward K. Williamson,1 Mariko Okumura,2 Kazuhiro Mochizuki,3 Emily J.H. Chen,1 Tae-Ju Park,1 Gudrun F. Debes,4 Yi Zhang,3 Tom Curran,1,2 Taku Kambayashi,2 and Janis K. Burkhardt1,2

1Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 2Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA. 4Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.

Effect of CRK proteins on T cell migration into inflamed tissues greatly exacerbates tissue destruction and disease severity in inflammatory diseases, including graft-versus-host disease (GVHD). T cell migration into such sites depends heavily on regulated adhesion and migration, but the signaling pathways that coordinate these functions downstream of chemokine receptors are largely unknown. Using conditional knockout mice, we found that T cells lacking the adaptor proteins CRK and CRK-like (CRKL) exhibit reduced integrin-dependent adhesion, chemotaxis, and diapedesis. Moreover, these two closely related proteins exhibit redundant function, as ectopic expression of either protein rescued defects in T cells lacking both CRK and CRKL. We determined that CRK proteins coordinate with the RAP guanine nucleotide exchange factor C3G and the adhesion docking molecule CASL to activate the integrin regulatory GTPase RAP1. CRK proteins were required for effector T cell trafficking into sites of inflammation, but not for migration to lymphoid organs. In a murine bone marrow transplantation model, the differential migration of CRK/CRKL-deficient T cells resulted in efficient graft-versus-leukemia responses with minimal GVHD. Together, the results from our studies show that CRK family proteins selectively regulate T cell adhesion and migration at effector sites and suggest that these proteins have potential as therapeutic targets for preventing GVHD.

CRK proteins are key regulators of adhesion and migration in many cell types. This family of ubiquitously expressed adaptors consists of CRKI, CRKII (products of the CRK gene), and CRK-like (CRKL), encoded by an independent gene, CRKL. CRKII and CRKL contain one SH2 domain followed by two SH3 domains (designated nSH3 and cSH3), whereas the splice variant CRKI lacks the cSH3 domain. The nSH3 domain of CRK proteins binds to C3G and DOCK180, which are guanine-nucleotide exchange factors (GEFs) for the small GTPases RAP1 and RAC1, respectively. RAP1 controls adhesion, while RAC1 controls actin polymerization. Binding of the SH2 domain of CRK proteins with p130Cas/CASL/EFS family proteins is important for localization of CRK to the plasma membrane. In contrast to the nSH3 and SH2 domains, the cSH3 domain of CRKII engages in intramolecular interactions that negatively regulate CRKII function by stabilizing a closed, autoinhibited state. In addition, CRKII and CRKL have a regulatory tyrosine (Y221 in CRKII, Y207 in CRKL) that is phosphorylated by ABL family kinases (7, 8). Phosphorylation of CRKII at Y221 creates a binding site for the SH2 domain, and the resulting intramolecular interaction blocks accessibility of the SH2 and nSH3 domains to other binding partners and terminates CRKII signaling (7). CRKI, which lacks the regulatory cSH3 domain and phosphorylation site, exhibits constitutively active adaptor function (4, 9).

Despite their importance in other cell types, the function of CRK proteins in T cells is poorly understood. Progress in this area has been hindered by the existence of profound developmental abnormalities in mice with germline deletion of CRK proteins.

Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: June 27, 2014; Accepted: December 11, 2014.
The majority of Crk-null and Crkl-null mice die during embryonic development; refs. 10, 11) and by problems posed by functional redundancy. The few studies that have been performed have focused on the T cell receptor (TCR) signaling pathway, and results are conflicting. Using the small number of surviving Crkl−/− mice, Peterson et al. showed that thymocyte number was reduced, but T cell differentiation and activation were intact (12). In contrast, Nolz et al. used RNAi to suppress CRKL expression in Jurkat cells and ex vivo human T cells and observed defects in integrin activation and cytokine production downstream of TCR engagement (13). Neither study addressed chemokine-dependent T cell responses, and neither addressed possible functional redundancy between CRKL and the closely related proteins CRKI and CRKII.

To circumvent developmental problems and allow analysis of T cells lacking all CRK proteins, we used mice bearing floxed alleles of both Crk and Crkl alleles (14) with Cd4-Cre transgenic mice (Crkfl/fl Crklfl/fl Cd4-Cre mice; hereafter called CRK/CRKL Dko mice). Some strains were further crossed to Rosa26-EYFP mice to monitor Cre expression (15). Analysis of CRK/CRKL Dko Rosa-EYFP mice showed that Cre expression was present in 95% of peripheral CD4+ and CD8+ T cells (data not shown). Western blotting of purified CD4+ T cells from Dko and WT mice revealed that levels of CRKI, CRKII, and CRKL in the mutant T cells were reduced by at least 95% (Figure 1A and data not shown), and flow cytometric analysis confirmed loss of CRK protein expression (Figure 1, B and C).

Figure 1. Crk and Crkl are deleted in T cells of CRK/CRKL Dko mice. (A) CD4+ T cells were purified from lymph nodes of CRK/CRKL Dko and WT mice. Preactivated T cells were prepared by stimulating with plate-bound anti-CD3 and anti-CD28 for 2 days and culturing without stimuli for an additional 5 days. Whole cell lysates were analyzed by SDS-PAGE and immunoblotted with anti-CRKL, anti-CRK, and anti-ZAP70. (B) Preactivated CD4+ T cells made as in A were fixed and permeabilized, and the intracellular staining of CRK (B) and CRKL (C) was determined by flow cytometry. (D) Thymus, spleen, and lymph nodes (LNs) were isolated from WT and CRK/CRKL Dko mice. Single-cell suspensions were analyzed by flow cytometry using the indicated antibodies. (E) Cated CD4+ and CD8+ T cells from lymph nodes (mixed peripheral and mesenteric lymph nodes) were analyzed for the indicated surface markers.

CRK/CRKL Dko mice were born at Mendelian ratios, and spleen, thymus, and lymph nodes exhibited normal cellularity (data not shown). Thymocyte populations were similar in WT and Dko mice, indicating that T cell development proceeded normally (Figure 1D). Peripheral lymphoid organs showed no differences in proportions of CD4+ and CD8+ T cells, naïve (CD62Lhi), memory (CD62LloCD44hi), or activated (CD69hi) T cell subsets (Figure 1, D and E, and data not shown). Thus, these mice represented a suitable source of mature CRK/CRKL Dko T cells for functional studies.

CRK/CRKL-deficient T cells show defects in adhesion and polarization. Since CRK proteins control adhesion in non-hematopoietic cells (4), we first asked whether integrin-dependent adhesion is defective in CRK/CRKL Dko T cells. On plates coated with ICAM-1, the ligand for the β2 integrin LFA-1, WT preactivated CD4+ T cells showed about 10% basal binding, which was increased 2- to 5-fold after stimulation with the chemokines CXCCL12 or CCL21, or anti-CD3 (Figure 2A). CRK/CRKL Dko T cells showed a significant reduction in adhesion to ICAM-1 under both basal and stimulated conditions. Indeed, chemokine stimulation induced almost no increased adhesion in these cells. Treatment with PMA bypassed the defect. This is most likely because the defect in CRK/CRKL Dko cells lies upstream of PKC signaling in the pathway leading to integrin activation, though PKC activation could also drive a parallel
ure 3, A and B, WT CD4+ T cells chemotaxed efficiently toward both CCL21 and CXCL10, chemokines that signal naive T cell trafficking into lymph nodes (18, 19) and Th1 cell trafficking to sites of inflammation (20), respectively. In contrast, CRK/CRKL Dko T cells displayed 20%–50% less migration toward both chemokines. These defects were not due to differences in the surface expression of the relevant chemokine receptors CCR7 and CXCR3 (Figure 3C). Similar results were obtained with CXCL12, a CXCR4 ligand that cooperates with CCR7 ligands to promote naive T cell trafficking across HEVs (ref. 21 and data not shown).

Since 2D migration (including Transwell assays) involves integrin function, we also tested chemotaxis in 3D collagen gels, where migration is integrin independent (22). Interestingly, CRK/CRKL Dko T cells chemotaxed efficiently toward both CCL19 and CCL21 in this setting (Figure 3D and Table 1). Comparison of multiple parameters including velocity, directionality, and forward migration index showed no significant differences between mutant and
WT cells. Thus, we conclude that loss of CRK proteins primarily impairs adhesion-dependent T cell migration; chemokine sensing is intact, and the response is sufficient to induce directional migration in settings where integrin-dependent adhesion is not required. 

CRK/CRKL-deficient T cells are defective in diapedesis. Firm adhesion is a prerequisite for T cells to transmigrate through the endothelial wall (extravasation/diapedesis) (2). To ask whether CRK proteins regulate diapedesis, T cells were monitored by time-lapse imaging while interacting with endothelial monolayers (untreated, or previously treated with TNF-α to upregulate ICAM-1 and VCAM-1 expression; data not shown). In this assay, cells that pass through the endothelial monolayer become phase-dark and flattened (see Supplemental Videos 1 and 2; supplemental material available online with this article; doi:10.1172/JCI77278DS1). Figure 4A shows a WT T cell undergoing diapedesis and a CRK/CRKL Dko cell that remained on the top of the monolayer. Quantitative analysis revealed that WT T cells showed robust diapedesis across TNF-α-treated endothelia, but CRK/CRKL Dko cells exhibited major defects (Figure 4B). Similar results were obtained using in vitro generated CRK/CRKL Dko Th1 cells (data not shown) and using an alternate assay in which endothelial cells were grown on Transwell inserts (Figure 4C).

Table 1. Chemotaxis in 3D collagen gels

<table>
<thead>
<tr>
<th>Experiment</th>
<th>CCL19</th>
<th>CCL21</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>y</strong> Forward migration index</td>
<td>Directionality</td>
<td>Velocity (mean ± SD)</td>
</tr>
<tr>
<td><strong>WT</strong></td>
<td><strong>Dko</strong></td>
<td><strong>WT</strong></td>
</tr>
<tr>
<td>Experiment 1, CCL19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>-0.22</td>
<td>0.37</td>
</tr>
<tr>
<td>Dko</td>
<td>-0.22</td>
<td>0.32</td>
</tr>
<tr>
<td>Experiment 2, CCL19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>-0.26</td>
<td>0.33</td>
</tr>
<tr>
<td>Dko</td>
<td>-0.25</td>
<td>0.33</td>
</tr>
<tr>
<td>Experiment 3, CCL21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>-0.24</td>
<td>0.33</td>
</tr>
<tr>
<td>Dko</td>
<td>-0.28</td>
<td>0.33</td>
</tr>
</tbody>
</table>
CRK and CRKL have partially overlapping function. Since the Transwell-based diapedesis assay showed robust and reproducible defects in CRK/CRKL Dko T cells, we used this assay to test functional redundancy among the 3 CRK isoforms. First, CRK/CRKL Dko CD4+ T cells were retrovirally reconstituted with CRKI, CRKII, or CRKL. As shown in Figure 4C, ectopic expression of any individual CRK isoform could fully rescue diapedesis, indicating overlapping function among CRK proteins. Retroviral transduction yielded 5- to 10-fold overexpression relative to endogenous protein levels (Figure 4D and data not shown), raising the possibility that this result stemmed from CRK protein overexpression. Thus, we also tested T cells from CRK or CRKL single knockout mice. These cells showed no compensatory changes in CRK protein expression (data not shown). As shown in Figure 4E, T cells lacking either CRK or CRKL alone showed defective diapedesis. CRKL-deficient T cells showed a more profound defect, similar in magnitude to that in Dko T cells. Thus, we conclude that CRK and CRKL are both required for optimal T cell diapedesis, with CRKL playing a more prominent role.

CRK and CRKL selectively promote activation of RAP1 and CDC42. We next asked what molecular pathways are controlled by CRK and CRKL to promote T cell adhesion and migration. No differences were observed between CRK/CRKL Dko T cells and WT cells in CCL21-induced ERK phosphorylation (Figure 5A), demonstrating that by this measure, Dko T cells respond to chemokine receptor stimulation as well as WT T cells. In non-hematopoietic...
cells, CRK proteins act upstream of C3G and DOCK180 to regulate activation of the small GTPases RAP1 and RAC1, respectively (4). We therefore performed effector pull-down assays to assess GTPase activation. In WT T cells, RAC1-GTP levels increased within 0.5 minutes after chemokine addition and remained elevated for 2–5 minutes (Figure 5, A and D). The kinetics of RAC1 activation varied somewhat among experiments, precluding averaging of results. Nonetheless, CRK protein deficiency consistently failed to affect the magnitude or the kinetics of RAC1 activation. In contrast, RAP1 activation was attenuated in CRK/CRKL Dko T cells (Figure 5, A and B). Similar defects in RAP1 activation were observed in CRK/CRKL Dko Th1 cells stimulated with CXCL10 (Figure 5, E and F). Finally, although CRK proteins have not been previously implicated in activation of CDC42, we also observed blunting of CDC42 activation in CRK/CRKL Dko T cells (Figure 5, A and C). Thus, we conclude that CRK proteins promote chemokine-induced activation of RAP1 and CDC42, but not RAC1.

CRK and CRKL coordinate C3G and CASL to regulate T cell diapedesis. Since RAP1 activation was defective in CRK/CRKL Dko T cells, we asked whether activation of the RAP1 GEF C3G was also perturbed. C3G was isolated from chemokine-stimulated WT and CRK/CRKL Dko T cells based on binding to recombinant CRKL-nSH3 (13), and tyrosine phosphorylation was assessed by immunoblotting. As shown in Figure 6B, phosphorylation of C3G was blunted in CXCL10-stimulated CRK/CRKL Dko T cells. Similar results were obtained after stimulation with CCL21 (data not shown). Parallel analysis was performed for CASL (CRK-associated substrate in lymphocytes), a critical regulator of T cell migration that interacts with the SH2 domain of CRK proteins (ref. 23 and Figure 6A). As shown in Figure 6C, tyrosine phosphorylation...
of CASL was almost completely abolished in Dko T cells, indicating that CRK proteins also promote CASL activation.

To further test the functional importance of CRK protein adaptor function, we made point mutations in the SH2 (R38K) or nSH3 (R169K) domain of CRKII to interrupt binding to CASL or C3G, respectively (24) (Figure 6A). WT or mutant CRKII proteins were expressed in Dko T cells, and diapedesis was analyzed. As shown in Figure 6D, diapedesis was rescued by reconstitution with WT CRKII but not with the R38K or the R169K mutants. In some settings, adaptor function of the CRKII SH2 and nSH3 domains is negatively regulated by phosphorylation at Y221; however, we found that a non-phosphorylatable CRKII Y221F mutant rescued T cell diapedesis no better than WT CRKII protein. Thus, either CRKII-dependent diapedesis is not repressed by phosphorylation or diapedesis is maximal and cannot be further upregulated under the conditions tested. Taken together, these studies show that adaptor function mediated by the SH2 and nSH3 domains of CRK proteins promotes activation of C3G and RAP1 as well as CASL, leading to enhanced T cell diapedesis.

**CRK and CRKL are dispensable for T cell homing but are required for migration to sites of inflammation.** To test CRK protein function in vivo, we first analyzed homing to lymphoid organs. First, resting CD4+ T lymphoblasts prepared from WT or CRK/CRKL Dko mice were mixed and injected into recipient mice, and short-term (1 hour) homing to lymphoid organs was assessed by flow cytometry. As shown in Figure 7A, the ratio of CRK/CRKL Dko to WT T cells was slightly less than 1 in lymph node and spleen and approximately 0.5 in blood. The reason for this diminished ratio is unclear and may reflect aberrant trapping of the mutant cells in non-hematopoietic tissues. Nonetheless, these data show that homing of CRK/CRKL Dko T cells to lymphoid organs is grossly normal. To circumvent the complexities associated with homing of resting T lymphoblasts, we also tested homing of naive T cells. Lymphocytes from CRK/CRKL Dko Rosa-EYFP (CD45.2') and B6.SJL (CD45.1') mice were mixed 1:1 and adoptively transferred into WT recipient mice (CD45.2'). To control for the genetic background of CRK/CRKL Dko and SJL mice, we performed parallel experiments using fluorescently labeled cells from WT littermates (CD45.2'), mixed with cells from B6.SJL mice. As shown in Figure 7B, the homing efficiency of naive CD4+ CRK/CRKL Dko T cells was virtually identical to that of WT T cells. This was also true for naive CD8+ T cells (data not shown).

Although we found that CRK proteins are not needed for homing to lymphoid organs, we reasoned that they might function in migration to inflamed tissues. To investigate this, we used a cutaneous delayed-type hypersensitivity model elicited by 2, 4-dinitrofluorobenzene (DNFB) to test Th1 entry into an inflamed site (25). Naive WT and CRK/CRKL Dko CD4+ T cells were skewed in vitro to become Th1 cells, and did so with equal efficiency (Figure 7C). WT and Dko Th1 cells were then fluorescently labeled, mixed, and transferred into DNFB-treated recipient mice. Trafficking of transferred cells was analyzed 24 hours later. Consistent with the homing experiments above, CRK/CRKL Dko Th1 cells migrated efficiently to lymphoid tissues. Interestingly, however, the mutant cells showed significantly reduced trafficking to inflamed skin (Figure 7D). Thus, we conclude that CRK proteins preferentially promote T cell migration to sites of inflammation in vivo.

**CRK/CRKL Dko T cells attenuate GVHD while preserving donor T cell-mediated GVL effects.** Since CRK proteins were important for migration into inflamed tissues, we reasoned that T cells lacking
cells, a process known as the GVL effect. Thus, devising ways to separate GVHD and GVL responses is critical for improving allogeneic BM transplant outcomes. One potential strategy involves retaining allogeneic T cells in lymphoid organs where leukemic cells reside, allowing GVL but not GVHD effects to occur (26). Based upon the differential migration of CRK/CRKL Dko T cells, we hypothesized that these cells might display intact GVL responses with reduced GVHD. To test this, we injected allogeneic BM-transplanted mice with or without purified WT or CRK/CRKL Dko CD8+ T cells and challenged them with host-type A20 lymphoma cells. BM-transplanted mice receiving lymphoma cells without any T cells exhibited rapid tumor growth and succumbed to the tumor within 2–3 weeks (Figure 8, D–G). BM-transplanted mice receiving WT T cells controlled tumor growth but died from GVHD within 30 days. In contrast, BM-transplanted mice receiving CRK/CRKL Dko T cells exhibited an equally potent GVL effect, but with significantly attenuated GVHD. Indeed, all recipients of CRK protein–deficient T cells survived to the end of the experiment. These results indicate that T cells that lacking CRK proteins can control GVHD while preserving beneficial GVL, leading to significantly improved survival of allogeneic BM transplant recipients.

Finally, to ask whether the ability of CRK/CRKL Dko T cells to carry out GVL with minimal GVHD is related to their differential migratory capacity, we analyzed T cell trafficking in the GVHD model using a competitive assay. CD8+ T cells purified from WT or CRK/CRKL Dko T cells were mixed with competitor WT T cells and injected together with T cell–depleted BM into allogeneic recipient mice. Ten to 12 days later, the ratios of adoptively transferred WT or Dko CD8+ T cells to competitor CD8+ T cells were compared in spleen and liver. As shown in Figure 8H, WT and competitor T cells migrated to liver and spleen with similar efficiency, with a ratio near 1 in both tissues. Dko T and competitor T cells also migrated with similar efficiency to spleen, as in Figure 7. In contrast to WT T cells, however, the Dko T cells showed a significant competitive disadvantage in trafficking to liver, a key GVHD target organ. Thus, the attenuated GVHD response we observe in mice transplanted with CRK/CRKL Dko T cells was at least partially attributable to defects in T cell trafficking into GVHD target organs.
Figure 8. CRK/CRKL Dko donor T cells can carry out GVL with minimal GVHD. (A–C) T cell–depleted bone marrow cells alone (BM, H-2b), mixed with purified WT CD4+ T cells (BM + WT CD4 T cells, H-2b), or mixed with purified CRK/CRKL Dko CD4+ T cells (BM + Dko CD4 T cells, H-2b) were injected into lethally irradiated BALB/c hosts (H-2d). Host GVHD clinical scores (A), body weight change (B), and survival (C) are summarized. Combined data from 2 different experiments are shown, with a total of 5–10 mice for each experimental group. (D–G) Lethally irradiated BALB/c hosts were injected with T cell–depleted bone marrow cells alone (BM control), or together with luciferase-transduced A20 cells (BM + A20luc), purified WT CD8+ T cells (BM + A20luc + WT CD8 T), or CRK/CRKL Dko CD8+ T cells (BM + A20luc + Dko CD8 T). Host body weight change (D), survival (E), and tumor burden (reflected by the luciferase signal) (F and G) are summarized. E shows combined data from 2 different experiments, with a total of 8–10 mice per experimental group. D and F show data from 1 of 2 independent experiments, with 5 mice for each experimental group. (H) To assess T cell migration during GVHD, congenically marked CD8+ T cells from WT or CRK/CRKL Dko mice were mixed 1:1 with competitor SJL T cells (all H-2b) and injected together with T cell–depleted bone marrow cells into lethally irradiated BALB/c host mice (H-2d). Spleen and liver were harvested after 10–12 days, and the ratio of experimental (WT or Dko) to competitor adoptively transferred cells was determined. Paired data (combined from 2 experiments) are shown, with a total of 5 (WT) or 6 (Dko) recipient mice. Error bars represent mean ± SD. Statistical analysis in C, E, and H was performed using a 1-way ANOVA.
Discussion

In this article, we show what we believe to be a novel role for CRK proteins in regulating chemokine-dependent adhesion, migration, and diapedesis of T cells, and we place these molecules in the signaling pathway linking chemokine receptor engagement to integrin activation. Surprisingly, we found that T cells lacking CRK proteins maintain effector function and the ability to home to lymphoid organs, but show selective defects in migration into inflamed tissues. This phenotype has important therapeutic implications, since T cells lacking CRK proteins can carry out effective GVL responses to leukaemia and maintain effector function and the ability to home to lymphoid organs. Additional studies show impaired transmigration across a TNF-α-activated endothelium and migrate poorly to sites of inflammation. Additional study will be needed to pinpoint the basis for this differential migratory capacity. It cannot be attributed to chemokine receptor (22), was normal. Although RAC1 activation was intact, activation of CDC42 was reduced in CRK/CRKL Dko T cells. This is an important finding, since CDC42 activity promotes T cell crawling along endothelial cells and probing for suitable sites for transendothelial migration (40). Evidently, the residual levels of CDC42 activation are sufficient to support directional T cell migration in the 3D collagen gel assay. Nonetheless, defects in CDC42 activity likely contribute to the diapedesis defects we observed. How CRK proteins regulate CDC42 is unclear. CDC42 may be activated downstream of RAPI (31), or other DOCK family proteins may be involved.

Since CRK proteins are best known as substrates for ABL family kinases, it is important to consider how ABL kinases fit into the pathways we have defined. Phenotypically, there are similarities and differences between CRK-deficient and ABL-deficient T cells. We reported previously that T cells lacking c-ABL show chemotactic defects in Transwell assays (41); however, these cells do not exhibit defective diapedesis (Y. Huang, unpublished observations). In vivo studies by Gu et al. (42) showed that T cells lacking ABL and ARG have defects in migration to lymphoid organs as well as to sites of inflammation. Thus, they lack the selective trafficking defects described here. Since ABL kinases typically negatively regulate CRK proteins (7), it seems paradoxical that loss of either ABL kinases or CRK adaptors impairs migration. Moreover, we found that mutating the ABL phosphorylation site in CRKII had no effect on diapedesis. The simplest explanation for this is that ABL kinases do not regulate diapedesis by phosphorylating CRK proteins at their inhibitory sites. Instead, we favor the idea that CRK proteins bring ABL kinases in proximity with other substrates. Gu et al. have shown that ABL kinases can phosphorylate CASL (HEF-1) and activate RAPI in response to chemokine stimulation. Thus, we propose a unified model through which CRK proteins bring ABL kinases in proximity with other substrates. Gu et al. have shown that ABL kinases can phosphorylate CDC42 and activate RAPI in response to chemokine stimulation. This likely explains our finding that in CRK/CRKL Dko T cells, CDC42 tyrosine phosphorylation is almost completely abolished.

Another important question is the extent to which CRK isoforms have unique versus overlapping functions. The SH2 and SH3 domains of CRKII and CRKL are highly conserved, their interaction specificities are almost identical, and redundancy has been reported in other pathways (14, 43, 44). However, there is also evidence for unique functions, since mice singly deficient for either CRK or CRKL exhibit severe developmental defects (10, 11). In T cells, we found that deletion of either gene alone led to defective diapedesis, with loss of CRK expression being particularly deleterious. Two possibilities are consistent with this finding: either CRK proteins cannot fully compensate for one another, or the overall expression level of all CRK isoforms is important. In support of the latter idea, we found that overexpression of any CRK isoform in doubly deficient cells could restore normal function. Thus, we conclude that CRKI, CRKII, and CRKL play partially overlapping roles in T cell adhesion and migration.

One of the most striking outcomes of this study is that although CRK/CRKL-deficient T cells can home to lymphoid organs, they show impaired transmigration across a TNF-α-activated endothelium and migrate poorly to sites of inflammation. Additional study will be needed to pinpoint the basis for this differential migratory capacity. It cannot be attributed to chemokine receptor binding, since chemokine receptor (37), while adhesion and transendothelial migration are fairly normal (38, 39). In contrast, we found that CRK/CRKL-deficient T cells exhibit clear defects in adhesion and diapedesis, with more modest defects in migration. Indeed, migration in a 3D environment, a process that depends on RAC1-driven actin polymerization but not on integrins...
signaling, since CRK/CRKL Dko T cells responded similarly to homing (CCL21, CXCL12) and inflammatory (CXCL10) chemokines. Differences in naive versus previously activated T cells are also unlikely, since effector Th1 cells reached lymphoid organs efficiently. The most attractive possibility is that CRK proteins are required for passage across postcapillary venules, but not for crossing HEVs. T cell integrins mediate firm adhesion to the endothelial wall and trigger signaling events within the endothelial cells that induce junctional weakening and promote T cell passage (45, 46). Thus, defective integrin activation in CRK/CRKL-deficient T cells could fail to trigger the appropriate endothelial response. The differences between postcapillary venules and HEVs are not fully understood, but it is clear that HEVs are highly specialized to regulate lymphocyte passage (47). In particular, HEV junctional complexes are more permeable, and they produce factors that trigger distinct T cell signaling events (48, 49). These HEV specializations may therefore circumvent the need for CRK protein signaling.

In many respects, the migration defects we observe in the immune system parallel defects in neuronal migration in the developing mouse cortex. Migrating neurons lacking both CRK and CRKL fail to pass through cortical preplate cells and earlier-born neurons, resulting in disruption, and apparent inversion, of cortical layers (14). As in T cell migration, the CRK/CRKL-C3G-RAP1 pathway is considered to play critical roles in Reelin-dependent neuronal migration. Therefore, it is possible that CRK and CRKL function to modulate the cell–cell interactions that allow migrating cells to pass through nonmigrating cell boundaries. It will be interesting to test the generality of this idea.

The differential migratory behavior of CRK-deficient T cells has important ramifications, since these cells can elicit strong GVL responses (which take place largely in lymphoid tissues) with minimal GVHD. Mice lacking CD18 or CCR7 also exhibit effective GVL activity associated with absent or attenuated GVHD responses (50, 51), as do mice lacking PKCθ (52). While these models are superficially similar, closer examination reveals important differences. For example, Ccr7–/– T cells show defects in trafficking to recipient lymph nodes, while Cd18–/– T cells migrate efficiently to lymph nodes but are defective in their ability to enter inflamed skin and GVHD target tissues such as intestine (50, 51). WT littermates were used as controls. BALB/c and B6/SJL mice were obtained from The Jackson Laboratory.

Cell isolation and culture. Naive CD4+ T cells were purified from lymph nodes and/or spleen by negative selection as previously described (41). To generate preactivated T cells, freshly isolated CD4+ T cells were stimulated in 24-well plates coated with 1 μg/ml anti-CD3 (2C11, BioXCell) and anti-CD28 (PV-1, BioXCell) at 37°C. Two days after stimulation, T cells were split into fresh non-stimulating wells and cultured for an additional 4–7 days. Experiments were performed 4–6 days after removal from anti-CD3/anti-CD28. Th1 cells were generated as previously described (25). Briefly, CD4+ T cells were seeded on anti-CD3- and anti-CD28–coated plates and cultured in the presence of 20 ng/ml IFN-γ (eBioscience), 5 ng/ml IL-12 (R&D Systems), and 1 μg/ml anti-IL-4 (Biological Resource Branch, National Cancer Institute, Frederick, Maryland, USA) for 3 days. Cells were then transferred to new plates and supplemented with the same concentrations of cytokines and 25 IU/ml rhIL-2 (obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH; rhIL-2 from Maurice Gately, Hoffmann-La Roche Inc.).

Retroviral transduction. cDNAs encoding CRKI, CRKII, CRKL, CRKII R38K, CRKII R169K, or CRKII Y221F were cloned into MigR1, which co-expresses eGFP from a bicistronic message, and production of high-titer retroviral supernatant in 293T cells was done as previously described (57). Primary CD4+ T cells were transduced after 2 days of plate-bound anti-CD3 and anti-CD28 stimulation. Cells were collected and re-seeded as 2.5 × 10^5/well in 24-well plates, and spin infected with freshly prepared retroviral supernatants, containing 2 μg/ml Polybrene (Sigma-Aldrich) at 850 g for 90 minutes at 25°C. After the spin infection, cells were washed and cultured with 100 IU/ml IL-2 for an additional 5 days in the absence of stimulation.
Reagents, antibodies, and flow cytometry. All reagents were from Sigma-Aldrich unless otherwise specified. Antibodies against CRK, RAPI, and RAC1 were from BD Biosciences. Anti-phospho-ERK p42/p46 was from Cell Signaling Technology Inc. Anti-CRKL (C-20) was from Santa Cruz Biotechnology. Anti-ZAP70 has been described previously (58).

For flow cytometry, single-cell suspensions were stained with the following fluorescently conjugated antibodies from BioLegend: B220 (RA3-6B2), CD25 (PC61), CD29 (HM-1-1), CD4 (RM4-5), CD44 (IM7), CD45.1 (A20), CD62L (MEL-14), CD69 (H1.2F3), CD8 (53-6.7), and CXCR3 (CXCR3-173) or with CD11a (2G17, BD Biosciences). Intraacellular labeling with mouse anti-CRK, followed by PE-conjugated anti-mouse IgG (BioLegend), and rabbit anti-CRKL, followed by Alexa Fluor 488–conjugated anti-rabbit IgG (Invitrogen), or alphaphosphocynin-conjugated IFN-γ (XM1G2.1, eBioscience) was performed as previously described (59). For intracellular labeling of IFN-γ, T cells were stimulated with PMA (50 ng/ml) and ionomycin (500 ng/ml) for 4 hours. Two hours prior to harvest, brefeldin A (1 μg/ml) was added to the cells. Cells were analyzed by flow cytometry using a FACS Calibur or LSR II (BD Biosciences). Analysis was carried out using FlowJo (Tree Star).

To detect CCR7 surface expression, cells were incubated with mouse CCL19-Fc (eBioscience) for 30 minutes at 4°C, washed, and incubated with biotin-conjugated anti-human IgG (Fc fragment specific, Jackson ImmunoResearch Laboratories) for 20 minutes. Cells were washed again, stained with PE-conjugated streptavidin (eBioscience), and analyzed by flow cytometry.

RAPI, CDC42, and RAC1 pull-down assay and C3G and CASL immunoprecipitation. T cells were stimulated with 10 nM CCL21 or CXCL12, lysed, and subjected to GST-RalGDS (for RAP1) or GST-PakRBD (for RAC1 and CDC42) precipitation as previously described (41). 1×10^7 T cell blasts per condition were used for each RAP1/CDC42 assay, and 5×10^6 cells per condition were used for each RAC1 assay. C3G immunoprecipitation was performed as previously described (13). Briefly, cells were chemokine stimulated, and lysates were incubated with GST-CRKL-nSH3 recombinant protein (from Daniel Billadeau, Mayo Clinic, Rochester, Minnesota, USA), followed by incubation with glutathione agarose resin (Thermo Scientific). For CASL immunoprecipitation, chemokine-activated cell lysates were incubated with anti-CASL (2G9, Abcam). The precipitants were immunoblotted for phospho-tyrosine (4G10, Millipore).

Adhesion and chemotaxis assay. Adhesion assays were performed as previously described (58) with some modifications. Ninety-six-well plates were coated with various doses of integrin ligands at 4°C overnight, then blocked with 2.5% BSA at room temperature for 1 hour. For ICAM-1, 96-well plates (Nunc MaxiSorp plate, Thermo Scientific) were coated with 100 μl of 0.5 μg/ml or 1 μg/ml recombinant mouse ICAM-1 (R&D Systems) per well. For fibronectin, 96-well plates (Costar plate 3596) were coated with 100 μl of 3 or 10 μg/ml human fibronectin (R&D Systems) per well. T cells were labeled with 2.5 μg/ml Calcein-AM (Invitrogen) at 37°C for 30 minutes, washed, and resuspended at 2×10^6/ml in PBS containing 2.5% BSA, Ca^2+, and Mg^2+. Fifty microliters of cells were added to each well and left to settle for 20 minutes on ice, followed by the addition of 10 nM chemokine, 1 μg/ml anti-CDS3 (500A2, BD Biosciences), or 10 ng/ml PMA. Cells were warmed in a 37°C water bath for 10 minutes. The unbound cells were washed off, and adherent cells were measured using a Synergy HT Multi-Mode microplate reader (Biotek). The percentage of T cell adhesion was calculated as fluorescence of adherent cells/total fluorescence of cells added to each microplate well.

Chemoaxis assays were performed as previously described (41). Ninety-six-well ChemoTx chambers (3-μm pore size, Neuroprobe) were filled with buffer with or without 10 nM chemokines in the bottom wells, and cells were applied to the upper wells. After 2 hours incubation at 37°C, migrated cells collected from the bottom wells were quantified by flow cytometry.

T cell polarization on fibronectin. Coverslips were acid washed by incubating in 10% H₂O₂ in 0.1 N HCl and then coated with 50 μg/ml fibronectin in PBS (containing Mg^2+ and Ca^2+) for 2 hours at room temperature. 5×10^4 preactivated CD4+ T cells made from WT or CRK/CRKL Dko mice were added to each coverslip and allowed to adhere for 30 minutes at 37°C. Cells were then fixed using 3% PFA in PBS. In each experiment, at least 50 T cells of each genotype were blindly scored based on whether they were unpolarized (circular cells) or polarized (cells with an obvious leading edge and uropod).

Diapedesis assay. 4×10^5 3B-11 endothelial cells (ATCC) were plated onto 35-mm plastic ibiDishes (ibidi) in DMEM with 10% FBS and incubated at 37°C overnight. Media was then replaced with DMEM containing 0.25% FBS. After 8–10 hours, some dishes were treated with 50 ng/ml TNF-α (PeproTech) to induce VCAM-1 and ICAM-1 upregulation. 2×10^6 WT or CRK/CRKL Dko preactivated CD4+ T cells were added to the 3B-11 monolayers. In some experiments, WT and CRK/CRKL Dko T cells were stained with 2 μM CFSE or 10 μM CellTracker Orange CMTMR (both from Invitrogen) the day before imaging. Fluorescently labeled WT and CRK/CRKL Dko T cells were mixed 1:1 and added to the 3B-11 monolayers. Cells were maintained at 37°C during imaging. Images were collected every 30 seconds for 2 hours on an Axiovert 200M microscope (Zeiss) using a ×20 LR objective and a CoolSnap FX-HQ camera (Roper Scientific). The T cells that underwent transendothelial migration were tracked and determined as percentage of total analyzed T cells.

As an alternative diapedesis assay, Transwell plate (Costar 3421) inserts were coated with 0.1% gelatin, and 3B-11 cells were grown on the insert overnight. The next day, 3B-11 cells were treated with 10–50 ng/ml TNF-α for 12–16 hours. T cells were then added to the insert, and 2 hours later, T cells that migrated through the inserts were collected and analyzed by flow cytometry.

3D chemotaxis. 3D chemotaxis was performed using tissue culture–treated μ-slide chemotaxis 3D chambers (ibidi). To produce collagen gels for migration studies, bovine skin collagen type I (PureCol, Advanced BioMatrix) was used at 1.6 mg/ml to make 5-μm-size pores (60). The collagen solution was neutralized and mixed with T cell blasts according to the manufacturer’s instructions, to yield a final concentration of 1× DMEM, 1.2% FBS, 0.3% NaHCO₃, and 1.6×10^6 T cells/ml. The collagen-cell suspension was loaded into the chambers and allowed to polymerize at 37°C, 5% CO₂ for 1 hour. 80 nM CCL19 or CCL21 in DMEM containing 1% FBS was added to one reservoir of each chamber, and DMEM containing 1% FBS was added to the opposite reservoir. Chambers were incubated for 30 minutes at 37°C to allow establishment of a linear chemokine gradient. Multiple chemotaxis chambers were visualized in parallel using a ×5 objective on a Zeiss Axiosview 200 M inverted microscope equipped with an automated stage and a 37°C environmental chamber. Images were collected at 1-minute intervals for 4 hours, using Slidebook 5.0 (Intelligent Imaging Innovations). Analysis was performed using the ibidi chemotaxis plugin for ImageJ, as described in ref. 61. Analysis was restricted to motile T cells by eliminating objects that were present in the field of...
view for less than 30 minutes and that displaced less than 15 μm. Population analysis of unfiltered data did not reveal significant differences in the proportion of motile T cells in WT and CRK/CRKL Dko samples.

**In vivo migration assays.** For T cell homing, purified CD8+ T cells from WT or CRK/CRKL Dko mice were activated with anti-CD3 and anti-CD28 for 3 days and rested for 4 days. These rested T cells were stained with CFSE or CMTMR and mixed 1:1, and a total of 1 × 10^7 to 2 × 10^7 cells was injected intravenously into sex-matched C57BL/6 recipient mice. One hour after injection, recipient mice were euthanized, and blood, lymph nodes, and spleen were collected. The ratios of Dko to WT CD4+ T cells were measured. To test naïve T cell homing, peripheral lymph node (subiliac, auxiliary, and cervical) cells were collected from B6.SJL (CD45.1+) and CRK/CRKL Dko Rosa-YFP (CD45.2+) mice, mixed at a ratio of 1:1, and injected into C57BL/6 recipient mice. Simultaneously, peripheral lymph node cells isolated from WT littermate control mice (CD45.2+) were labeled with 0.2 μM CFSE, mixed with B6.SJL cells at a ratio of 1:1, and injected into different recipient mice. One hour after adoptive transfer, recipient mice were euthanized; blood, lymph nodes, and spleens were collected and the frequency of transferred naïve T cells (CD44+, CD62L+) was quantified by flow cytometry. The inflammation assay was performed as previously described (25). To induce a cutaneous inflammation, 0.5% DNFB was dissolved in acetone–olive oil (4:1) and applied to recipient mice (C57BL/6 mice) by skin painting on day –21 and day –20. On day –1, recipient mice were challenged with 0.3% DNFB. WT or CRK/CRKL Dko Th1 cells were labeled with 1 μM CMTMR and mixed at a ratio of 1:1, and 1 × 10^7 to 2 × 10^7 T cells were injected intravenously. Twenty-four hours after adoptive transfer, recipient mice were euthanized; blood, lymph nodes, spleens, and skin were collected; and the frequency of transferred WT and CRK/CRKL Dko T cells was quantified by flow cytometry. All inflammation experiments were performed side-by-side with reciprocal staining. Each in vivo experiment was conducted with pooled donor cells from at least 3 mice per genotype to minimize donor-to-donor variations. The migration index was calculated as Dko adoptively transferred/WT adoptively transferred, normalized to Dko input/WT input. 

**GVHD and GVL.** For GVHD, CD8+ T cells were purified from WT or CRK/CRKL Dko mice, mixed with T cell–depleted bone marrow (TCD-BM) cells that were prepared from C57BL/6 mice, and injected into lethally irradiated BALB/c mice (8 Gy × 2). Body weight and GVHD scores were assessed as described previously (62). For GVL, purified CD8+ T cells from WT or CRK/CRKL Dko mice were mixed with TCD-BM and A20 cells that express luciferase and injected into irradiated BALB/c mice. The bioluminescent signal intensity was determined after intraperitoneal injection of 4.5 mg Firefly d-luciferin (Biosynth) using the IVIS 200 system (Xenogen). The survival and body weight changes of the recipient mice were assessed.

To assess T cell migration during the GVHD, CD8+ T cells were sorted by flow cytometry from WT or CRK/CRKL Dko mice (CD45.2+, Thy.1+) and mixed 1:1 with FACS-sorted CD8+ T cells from B6.SJL mice (CD45.1+, Thy.1+). These CD8+ T cells were injected together with TCD-BM (Thy.1+) into lethally irradiated BALB/c mice. On day 10–12, the recipient mice were sacrificed, and the spleen and liver were harvested. The ratio of adaptively transferred CD8+ T cells (all H2Kb+, Thy.1+) from experimental (WT or Dko, both CD45.2+) versus competitor (B6.SJL, CD45.1+) mice was determined by flow cytometry. Statistics. Bar graphs represent mean ± SD. Data were analyzed using Excel or Prism 5.0 (GraphPad Software). Statistical significance was tested using paired or unpaired 2-tailed Student’s t tests or ANOVA as appropriate, with P < 0.05 set as a cutoff for significance.

**Study approval.** Animals were maintained and procedures were performed with approval of the IACUCs of the Children’s Hospital of Philadelphia and the University of Pennsylvania School of Medicine.

**Acknowledgments**

We thank Drew Comrie and other members of the Burkhardt laboratory for helpful discussions and critical reading of the manuscript. We also thank the flow cytometry cores at the University of Pennsylvania and the Children’s Hospital of Philadelphia for valuable assistance. This work was supported by NIH grant K01 AR057577 to Y. Huang, R01 AI065644 to J.K. Burkhardt, T32 HL007775 to M. Karimi, T32 TCA009140 to N.H. Roy, and R01AR056780 to G.F. Debes. This work was also supported by a Pennsylvania Department of Health CURE formulary grant (SAP#4100047628) to T. Curran.

Address correspondence to: Yanping Huang, Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, 3615 Civic Center Boulevard, 815 Abramson Research Center, Philadelphia, Pennsylvania 19104, USA. Phone: 267.426.5523; E-mail: huangy@email.chop.edu. Or to: Janis K. Burkhardt, Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, 3615 Civic Center Boulevard, 816D Abramson Research Center, Philadelphia, Pennsylvania 19104, USA. Phone: 267.426.5410; E-mail: jburkhar@mail.med.upenn.edu.

Yi Zhang’s present address is: Department of Microbiology & Immunology, Fels Institute for Cancer Research & Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.


